TABLE 3.
Phase II IgG: statistical analysis of five commercial ELISA kits compared to IFATa
| ELISA test phase II IgG | Total no. of tests | No. of IFAT-positive results | % (95% CI) |
P (χ2 test) | |
|---|---|---|---|---|---|
| Sensitivity | Specificity | ||||
| Virion/Serion | 70 | 38 | 68.42 (51.35–82.5) | 100.00 (89.11–100.00) | 3.59E−09 |
| Biomed | 68 | 38 | 55.26 (38.3–71.38) | 100.00 (88.43–100.00) | 9.70E−07 |
| Mikrogen | 68 | 38 | 68.42 (51.35–82.5) | 100.00 (88.43–100.00) | 8.17E−09 |
| IBL | 68 | 38 | 76.32 (59.73–88.56) | 100.00 (88.43–100.00) | 2.65E−10 |
| Abbott | 70 | 38 | 100.00 (90.75–100.00) | 100.00 (89.11–100.00) | 5.93E−17 |
a
The values for each test are reported as the determined Q fever phase II IgG level versus the IFAT result. 95% CI, 95% confidence interval.